Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.
about
β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.Epigenetic Strategies to Boost Cancer Immunotherapies.Hurdles to the Development of Effective HBV Immunotherapies and HCV VaccinesAtezolizumab for the treatment of non-small cell lung cancer.Is autoimmunity the Achilles' heel of cancer immunotherapy?De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation.Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.Cutting Edge: Chromatin Accessibility Programs CD8 T Cell Memory.The Principles of Engineering Immune Cells to Treat Cancer.Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Successful and Maladaptive T Cell Aging.Metabolic and Epigenetic Coordination of T Cell and Macrophage Immunity.Transcriptional and epigenetic regulation of T cell hyporesponsiveness.Molecular Dissection of CD8+ T-Cell Dysfunction.NK Cell Exhaustion.T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose.Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells.Can T cells be too exhausted to fight back?Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue.Immune checkpoint blockade in infectious diseases.PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination.Role of PD-1 in Immunity and Diseases.PD1 functions by inhibiting CD28-mediated co-stimulation.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.Chromatin states define tumour-specific T cell dysfunction and reprogramming.Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.Gene Regulatory Network Rewiring in the Immune Cells Associated with Cancer.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells.Informatics for cancer immunotherapy.According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.The diverse functions of the PD1 inhibitory pathway.Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Inhibitors of the PD-1 Pathway in Tumor Therapy.The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy.Mechanisms of resistance to immune checkpoint inhibitors.
P2860
Q33578997-B89D979B-357E-421E-A8E8-EF70216135E9Q33838340-F7DA2477-661A-41E5-AFDC-8AC1A0DBD3BEQ33840260-A5C68FF1-776B-4444-A3F1-7139002AC6E0Q38675969-DB004F35-B94B-4B31-B362-7203E12D3A87Q38687375-8F540CD4-BF86-481A-9252-8D4F60CA3323Q38709894-2C85D19B-AAA1-42F2-94C9-444D4C6A8004Q38727885-F3500A26-EBD1-4BC9-96B2-8230C8505820Q38971108-DC003AE0-DA15-4F6E-BB5D-8ECED9C9D8EAQ39130457-A92934CA-1147-4662-AC9F-CE0B1B481F47Q39178061-8D7C409E-DA3E-4164-84A9-D6EC0634630AQ39193878-FAD18B44-19E6-41AE-BF3E-6AB79EFED9FCQ39313214-C7EFF90E-F20C-4E7C-82D4-B16939C0495BQ39367810-2095D4F6-0B54-4A7E-BFC6-D569B46ADC2AQ39405489-EB549F6A-8538-4FED-A107-949630027BCBQ39431541-27ACD423-A3B5-49CE-B368-C279CF2457DAQ40248504-CB83B808-FCEC-4B5B-A7D7-C2F2B8EF70E6Q40296362-73D5FF21-9913-4BAB-9581-92F1BA386B7FQ40297266-D9B1CAA1-1F80-4985-A3C1-C9148C7C6E37Q40433100-22C54EF6-2D4F-456F-818D-26E19C2093E5Q41694140-FC318E56-BCD6-4D55-8DF6-2198E3B64CB2Q41921732-CDF1D454-9C38-4DC9-9A29-533934E2EBD7Q41931832-EF1A7BA8-91AD-4CB6-88D4-0592C1527112Q41934141-3DA8A573-F94E-4DD9-9FFD-374A499AB77DQ42332962-9A1FE8A9-67B8-4B4F-8086-F571AE9B0D60Q42369857-6F6403B0-9F45-4115-9515-EFB83454E390Q46060358-92F2B94C-4C89-4800-9506-9DC3720E6A8CQ47094002-51BF016E-CF6C-4FD7-A8B4-5C2421535FECQ47095688-D3F34715-8A00-4E95-80B5-BCC97A04DA83Q47120629-0D34A709-A158-4F95-8830-0329CD528FA8Q47137043-AD3AD797-543A-4E3F-ADA3-B7B300128890Q47215596-272079FB-F4DF-4575-8735-DA941EAA6718Q47290509-9458CA25-0FF1-4F75-A537-83CA729ED8EEQ47593614-53C874F4-C062-4A3B-9935-175BA89F421FQ47678849-268295B1-3719-47D6-B07C-BF8E11BF9B5DQ47958949-CD077CDE-975D-4C1D-B371-1C5C1409D15EQ47970734-2337E7CE-2113-4242-943A-718B7DCBC66FQ48185876-2D1D47D8-3FC4-470E-823D-ACB814D62024Q48293633-E7BDDAF2-5AB2-4D23-B1F7-8F4E0C4B4BA0Q49307766-AE040C54-04AD-4BE4-944E-A71F532ACE67Q49537326-ED39C417-F3F5-45B2-9FBD-3BDC9807D70C
P2860
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Epigenetic stability of exhaus ...... invigoration by PD-1 blockade.
@ast
Epigenetic stability of exhaus ...... invigoration by PD-1 blockade.
@en
type
label
Epigenetic stability of exhaus ...... invigoration by PD-1 blockade.
@ast
Epigenetic stability of exhaus ...... invigoration by PD-1 blockade.
@en
prefLabel
Epigenetic stability of exhaus ...... invigoration by PD-1 blockade.
@ast
Epigenetic stability of exhaus ...... invigoration by PD-1 blockade.
@en
P2093
P2860
P50
P356
P1433
P1476
Epigenetic stability of exhaus ...... invigoration by PD-1 blockade.
@en
P2093
Adam M Drake
Alexander C Huang
Bertram Bengsch
Debattama R Sen
E John Wherry
Golnaz Vahedi
Jernej Godec
Kristen E Pauken
Makoto Kurachi
Morgan A Sammons
P2860
P304
P356
10.1126/SCIENCE.AAF2807
P407
P577
2016-10-27T00:00:00Z